Iopamidol vs metrizamide: a double blind study for cervical myelography.
A double-blind study was performed on 20 patients comparing the safety and efficacy of Iopamidol and Metrizamide in cervical myelography. The radiographic qualities of the Iopamidol and Metrizamide examinations were equivalent when using the same volume (12 to 13 ml), concentration (200 mg I/ml), and a C1-2 route of administration. The performance of a CT scan on selected patients in specified areas of interest provided additional diagnostic information in some patients (e.g syringomyelia, degenerative spondylosis). The adverse reactions were mild in the Iopamidol group with 4 of the 10 patients experiencing no adverse reactions. The more severe reactions, including disorientation, agitation, dysarthria, asterixis, hyperreflexia and EEG abnormalities were limited to the Metrizamide group with one or more occurring in 2 of the 10 patients studied. Only one Metrizamide patient experienced no adverse reactions. In this study containing a limited number of patients, Iopamidol was shown to be a diagnostically effective and safer contrast medium for performing cervical myelography.
D055598:Chemical Phenomena; D002621:Chemistry; D004311:Double-Blind Method; D006801:Humans; D007479:Iopamidol; D007483:Iothalamic Acid / Q000009:adverse effects / Q000031:analogs & derivatives*; D008793:Metrizamide / Q000009:adverse effects; D009192:Myelography; D013118:Spinal Cord Diseases / Q000000981:diagnostic imaging; D013122:Spinal Diseases / Q000000981:diagnostic imaging
D007483:Iothalamic Acid; D007479:Iopamidol; D008793:Metrizamide